3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Ovarian Neoplasms
24
Fallopian Tube Neoplasms
20
Breast Neoplasms
10
Carcinoma, Ovarian Epithelial
8
Sarcoma
6
Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Sarcoma, Kaposi
2
Sarcoma, Ewing
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multi-centric Castleman's Disease
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Leiomyosarcoma
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Acquired Immunodeficiency Syndrome
2
AIDS-related Kaposi sarcoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
liposomal doxorubicin
×
1 year
×
Clear all
NCT06312176
2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled